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ABSTRACT
Aim of the study. Postural deformities are common in Parkinson’s disease (PD) patients. Several treatment options have been 
reported, but responses to these treatments appear unpredictable. Istradefylline is a novel drug for PD. Cases of PD patients 
whose postural deformities were improved after withdrawal of dopamine agonists and initiation of istradefylline are presented.
Materials and methods. Four consecutive patients with postural deformities including antecollis, Pisa syndrome, and campto-
cormia were recruited and treated with istradefylline in combination with withdrawal of dopamine agonists, which are possible 
causes of postural deformities.
Results. The dopamine agonists were discontinued an average of 26 months after the development of the postural deformities, 
and istradefylline was initiated an average of 1.3 months after dopamine agonist withdrawal. Three patients with preserved 
paraspinal muscle volume showed good responses to the treatment regimen at least two months after dopamine agonist 
withdrawal.
Conclusions and clinical implications. Postural deformities caused by dopamine agonists generally improve less than two 
weeks after dopamine agonist withdrawal. Given the response time in the present study, the response was unlikely to be caused 
solely by dopamine agonist withdrawal. Istradefylline can be a potential therapeutic option; however, appropriate selection of 
patients for treatment with istradefylline is warranted.
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Introduction 
Patients with Parkinson’s disease (PD) often develop 
postural deformities including camptocormia, antecollis, 
Pisa syndrome, and scoliosis [1]. Possible pathophysiological 
mechanisms for postural deformities, such as dystonia, rigidity, 
myopathy, impaired proprioception, spine structural changes, 
and impaired spatial perception, have been proposed [1]. Po-
stural deformities can be induced by several drugs, including 
amantadine, levodopa, and valproic acid. Dopamine agonists 
can also induce postural deformities, and withdrawal of the 
dopamine agonist alone may lead to prompt symptom relief. 
However, withdrawal of the dopamine agonist may worsen 
the motor symptoms of PD. Other treatment options inclu-
ding deep brain stimulation and botulinum toxin injection 
are available, but they are unsatisfactory in some patients 
[2]. Istradefylline, an adenosine A2A receptor antagonist, is 
a novel non-dopaminergic drug available for the treatment of 
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PD in Japan [3]. A clinical trial of istradefylline for PD patients 
showed reduced off time and improved Unified Parkinson’s 
Disease Rating Scale motor scores. However, a 12-week, 
double-blind study to assess the efficacy of istradefylline 
failed to prove efficacy in improving motor symptoms [4]. 
The detailed pharmacokinetics of istradefylline are unknown.
Very recently, Suzuki et al. reported that nine of 18 PD 
patients with postural abnormalities who were treated with 
istradefylline showed a significant improvement (p < 0.05) 
in posture, as assessed using the sub-score for posture on the 
Movement Disorder Society revision of the Unified Parkinson’s 
Disease Rating Scale part III [5]. Possible mechanisms underly-
ing the response to the therapy have been previously suggested 
[6]. Postural deformity can be caused by dystonia, and blockade 
of A2A receptors was shown to restore the impairment of synap-
tic plasticity in dystonia mice. Another potential mechanism is 
that an inadequate dose of anti-parkinsonian drugs could be one 
of the causes of postural deformity that can be ameliorated by 
istradefylline, which can decrease the off-periods [7].
However, that study did not clarify which factors affect 
response. In addition, the clinical details of each patient were 
not described in that report. The cases of four PD patients 
with postural deformities who were treated with istradefylline 
in combination with dopamine agonist withdrawal are here 
presented. Three patients showed improvements in postural 
deformities without deterioration of motor function. The 
details of the patients’ clinical disease courses are presented, 
along with the possible predictors of postural improvement 
with istradefylline.
Materials and methods
The clinical charts of 103 PD patients who visited the 
Department of Neurology at our hospital between 1 April, 
2015 and 31 March, 2016 were reviewed, and four PD patients 
with postural deformities were identified. Treatment with 
istradefylline was then begun after obtaining their informed 
consent for treatment. The clinical diagnosis of PD was made 
by board-certified neurologists (SF, TM, JF, YT) according to 
the UK Brain Bank Clinical Diagnostic Criteria [8]. Patients 
with previous spinal bone fractures were excluded, as were 
patients who had mild postural deformities that did not 
impact upon daily life. Data on demographics and clinical 
and magnetic resonance imaging (MRI) findings for patients 
treated with istradefylline were retrieved.
All experimental procedures were conducted in accordan-
ce with the policies and ethical principles of the Declaration 
of Helsinki. This study was approved by the Ethics Committee 
of our institution.
Results 
The patients’ mean age at PD onset and mean disease 
duration were 69 (standard deviation (SD) 7.0) years and 
5 (SD 0.5) years, respectively. The mean Hoehn and Yahr stage 
was approximately 3. The detailed clinical courses of the four 
patients are presented below.
Patient 1 developed clumsiness in the upper right limb 
at 73 years of age. She was diagnosed with PD and started on 
ropinirole at 74 years, with amelioration of her symptoms. She 
began to take levodopa at 76 years. She showed a forward-bent 
posture that had gradually worsened, and she also developed 
a dropped head during the disease course (Fig. 1A). Zonisa-
mide and selegiline were added during the disease course, but 
the postural deformity did not respond to the medication. 
Neurological examination showed camptocormia and ante-
collis. Ropinirole was withdrawn, and istradefylline (40 mg/
day) was simultaneously started at 77 years. Two months after 
the initiation of istradefylline, the postural abnormalities 
gradually improved, and she showed normal posture for an 
elderly person three months after beginning istradefylline (Fig. 
1B, C). MRI showed good preservation of paraspinal muscle 
volume (Fig. 1D-G).
Patient 2 presented with a gait disturbance at 72 years of 
age and was diagnosed with PD at 74 years. She started taking 
levodopa, and pramipexole was subsequently added, which im-
proved her parkinsonism considerably. She developed a drop-
ped head at 74 years (Fig. 1H). Selegiline and entacapone were 
added at 74 and 75 years, respectively. Pramipexole was changed 
to ropinirole at 76 years. Botulinum toxin injection for the 
sternocleidomastoid muscles did not improve her symptoms 
at the age of 77 years. On neurological examination, she had 
camptocormia and antecollis, and ropinirole was discontinued 
at 79 years. Two months after discontinuation of ropinirole, 
istradefylline (40 mg/day) was started. Two months after the 
initiation of istradefylline, postural abnormalities showed gra-
dual improvement, and normal posture for an elderly person 
was restored three months after beginning istradefylline (Fig. 
1I, J). MRI showed mild paraspinal muscle atrophy (Fig. 1K-N).
Patient 3 developed a tremor in the upper right limb at 
62 years of age. She was diagnosed with PD at 63 years. She 
was first given levodopa, which ameliorated her parkinsonism. 
She started to take rotigotine and amantadine during the 
course of the illness. She developed lateral trunk flexion at 
66 years, with gradual deterioration (Fig. 1O). On examina-
tion, she showed Pisa syndrome. Rotigotine was withdrawn, 
and zonisamide and trihexyphenidyl were added, but the 
symptoms did not improve. One month after withdrawal of 
rotigotine, istradefylline (40 mg/day) was started. Six months 
after initiating istradefylline, her postural abnormalities were 
mildly improved (Fig. 1P). MRI showed mild atrophy of the 
paraspinal muscles (Fig. 1Q-T).
Patient 4 developed a resting tremor and motor slowness 
in the lower left limb at 59 years. She was diagnosed with PD 
at 60 years, and she started taking levodopa and pramipexole, 
which improved her symptoms. She presented with a drop-
ped head at 67 years. Despite adjustment of anti-parkinso-
nian drugs, parkinsonism and the dropped head gradually 
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Figure 1. Description of patients before and after initiation of istradefylline and MRI observations.
Patient 1 presented with camptocormia and antecollis (A), which improved greatly after initiation of istradefylline (B, C). MRI T1WI (D-G) shows 
well-preserved paraspinal muscle volume. Patient 2 showed antecollis (H) that improved greatly three months after initiation of istradefylline 
(I, J). Patient 3 showed Pisa syndrome (O), which was partially ameliorated after initiation of istradefylline (P). MRI T1WI examinations of both 
patients (K-N: Patient 2; Q-T: Patient 3) show relatively preserved paraspinal muscle volume. Patient 4 showed antecollis (U) and experienced no 
improvement after initiation of istradefylline (V). MRI T1WI examination of Patient 4 (W-Z, a, b) shows moderate atrophy of the paraspinal muscles
worsened (Fig. 1U). On neurological examination, she had 
antecollis; the pramipexole was reduced, and istradefylline was 
started at 70 years. Pramipexole was withdrawn two months 
before starting istradefylline (40 mg/day). However, even eight 
months after initiation of istradefylline, the dropped head 
had not improved (Fig. 1V). MRI (T1WI) showed moderate 
atrophy of the paraspinal muscles (Fig. 1W-Z, 1a, 1b).
The demographic and clinical data of the patients are set 
out in Table 1.
Discussion
The clinical courses of four PD patients with postural de-
formities who were treated with istradefylline in combination 
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Table 1. Summary of demographic and clinical data of four PD patients with postural deformities
Patient AAO 
(years)
DD 
(years)
H&Y 
stage
Type of  
postural  
deformities
Combined medica-
tions before initiation 
of istradefylline (/day)
Period A 
(months)
Period B 
(months)
Period C 
(months)
Period D 
(months)
1 73 4 3 Camptocor-
mia,
antecollis
Levodopa 300 mg
Ropinirole 6 mg
Zonisamide 25 mg
Selegiline 2.5 mg
8 12 0 2
2 72 7 4 Antecollis Levodopa 600 mg
Ropinirole 8 mg
Droxidopa 600 mg
6 60 2 2
3 62 4 3 Pisa syndro-
me
Levodopa 200 mg
Rotigotine 18 mg
Amantadine 100 mg
10 6 1 6
4 59 11 3 Antecollis Levodopa 450 mg
Pramipexole 8 mg
Zonisamide 25 mg
84 36 2 NA
AAO – age at onset; DD – disease duration; H&Y – Hoehn & Yahr; NA – not applicable;
Period A – period between initiation of dopamine agonist and onset of postural deformities;
Period B – period between onset of postural deformities and withdrawal of dopamine agonist;
Period C – period between withdrawal of dopamine agonist and initiation of istradefylline;
Period D – period between initiation of istradefylline and improvement of postural deformities
with the withdrawal of dopamine agonists are here presen-
ted. Patient 1 showed camptocormia and antecollis, Patient 
2 showed antecollis, Patient 3 showed Pisa syndrome, and 
Patient 4 had antecollis. All patients had initially been trea-
ted with levodopa/carbidopa and a dopamine agonist before 
the development of postural deformities. One of the most 
common causes of postural deformities seen in PD is medi-
cations, especially dopamine agonists. Thus, the dopamine 
agonists were stopped, and the patients were treated with 
istradefylline during the disease course to avoid deterioration 
of motor function. For Patient 1, istradefylline was started at 
the same time as dopamine agonist withdrawal. For the other 
patients, istradefylline was initiated at least two months after 
dopamine agonist withdrawal. Three of the four PD patients 
showed clinical improvement of postural deformities at least 
two months after dopamine agonist withdrawal. Postural de-
formities caused by dopamine agonist medications generally 
improve relatively quickly (≤ 2 weeks after dopamine agonist 
withdrawal). Given the response time seen in the presented 
patients, the clinical response was unlikely to have been caused 
solely by dopamine agonist withdrawal. In addition, a very 
recent report by Suzuki et al. showed improvements in postural 
deformities with istradefylline treatment [5].
Paraspinal muscle volume is considered to predict impro-
vement of postural deformities by deep brain stimulation. Saki 
et al. performed subthalamic deep brain stimulation in 14 PD 
patients with camptocormia and showed significantly higher 
paraspinal muscle volume in patients who responded well to 
therapy compared to those who showed partial or no response 
[9]. In the presented cases, MRI showed preservation of pa-
raspinal muscle volume in Patients 1–3, who showed good to 
mild improvement with istradefylline, whereas Patient 4, who 
showed no clinical improvement, showed moderate atrophy of 
the paraspinal muscles. As for deep brain stimulation, paraspi-
nal muscle volume is a potentially good predictor of success 
when treating postural deformities in PD with istradefylline.
The exact pharmacokinetics of adenosine A2A receptor 
blockade remain unclear. Dystonia is one cause of postural 
deformities. Napolitano et al. reported that adenosine A2A 
receptor blockade rescues physiological synaptic plasticity, 
leading to an improved phenotype in DYT1 mutant mice [10]. 
The pedunculo-pontine tegmental nucleus is associated with 
muscle tone control. Another potential mechanism is that 
adenosine A2A receptor blockade by istradefylline inhibits 
basal ganglia output through an indirect pathway that leads to 
amelioration of excess inhibition of this nucleus [11].
One limitation of this study was the absence of quantitative 
evaluation of postural deformities. Another limitation is the 
absence of strategic methods for MRI acquisition to assess 
muscle volume. In addition, due to the retrospective nature of 
this study, some clinical information was missing.
Clinical implications/future directions
Postural deformities greatly impair patients’ activities of 
daily living and unquestionably lead to worsening of their 
quality of life; therefore, novel therapies are needed. Given 
the limited availability of pharmacological agents for postural 
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deformities, istradefylline is a potential therapeutic option. 
Dopamine agonist withdrawal may lead not only to an im-
provement in postural deformity, but also to a deterioration 
of parkinsonism. Conversion from a dopamine agonist to 
istradefylline is potentially safe and beneficial for patients 
with postural deformities, without leading to deterioration 
of motor symptoms.
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